Navigation Links
China Sky One Medical, Inc.'s AMI Diagnostic Kit Recognized as a National Innovation Project by NDRC
Date:1/12/2010

HARBIN, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company's AMI Diagnostic Kit for early detection of heart disease was recognized by the National Development and Reform Commission (NDRC) as a "National Innovation Project," a designation given to innovative projects in key high technology industries.

The AMI Diagnostic Kit, which was developed by China Sky One Medical's wholly owned subsidiary, Harbin First Bioengineering Company, was nominated for the prestigious designation in early 2009, when the NDRC began the selection process for National Innovation Projects. Following a rigorous one-year review and evaluation by the NDRC, the Company's AMI Diagnostic Kit won the title because it represents leading global technology, has promising market potential, and because the developer owns all the related intellectual property rights. The official document for the title is NDRC No. 2561.

"We are inspired by the fact that our AMI Diagnostic Kit has been recognized as a National Innovation Project," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We are committed to becoming an industry leader in the research and development of high technology medical products and now have nine new diagnostic kits under development, which we believe will enhance our competitive position and contribute to our future growth."

Recipients of the National Innovation Project designation will receive a subsidy from the Chinese government of RMB 6.00 million (approximately US $0.88 million) in 2010. In addition, National Innovation Projects receive a preferential income tax rate of 15%, versus the regular tax rate of 25%. Currently, three of China Sky One Medical's wholly-owned subsidiaries, Harbin TDR Medical Science and Technology, Heilongjiang Tianlong Pharmaceutical, and Harbin First Bioengineering, receive a preferential income tax rate of 15% because they have been granted the High-Technology Enterprise Certificate by the provincial government in Heilongjiang Province, which became effective January 1, 2009.

The AMI Diagnostic Kit, which entered the market in China in 2007, is used for early diagnosis of Myocardial Infarction (MI), also known as heart disease. The testing kit requires users to place a blood sample on a marker, and a positive (+) or negative (-) sign will result, showing whether the user should consult his or her doctor for further testing. More often than not, heart disease is likely to strike people who are overweight, smoke, or suffer from diabetes. Statistics show that over 60 million patients in China currently suffer from heart disease, with approximately eight million new cases each year. Recent medical studies have shown that heart failure and heart attacks are increasing among the younger adults in China, the result of several factors, including the fast pace of a more modern life style and increased pressure from work and school. Using the AMI Diagnostic Kit for early detection of heart disease can help to reduce these statistics. For the first nine months of 2009, the AMI Diagnostic Kit accounted for approximately 7.5% of the Company's total revenues.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio-Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.cski.com.cn .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include expectations of future growth or information regarding the recognition of AMI Diagnostic Kit as a National Innovation Project by NDRC. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Stanley Hao, CFO
     Phone: +86-0451-8703-2617
     Email: stanleyhao@cski.com.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

     Mr. R. Micchelli, Sr. Financial Writer
     Phone: +1-646-454-4516
     Email: richard.micchelli@ccgir.com

SOURCE China Sky One Medical, Inc.

RELATED LINKS
http://www.cski.com.cn
http://www.ccgirasia.com

'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaron Expands Portfolio of Services with Acquisition of Bridge Laboratories China
2. China Medicine Announces Changes to Management Team
3. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
4. Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group
5. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
6. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
7. China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010
8. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
9. China Biologic Products Approved to List on NASDAQ
10. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
11. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Global Health Intelligence (GHI), the leading healthcare data analytics ... 2017 ranking of the Best-Equipped Hospitals in Latin America ... GHI,s hospitals database for Latin America , which is ... database covers 86% of the hospitals in Latin ... each institution in key areas such as beds, medical specialties, ...
(Date:5/9/2017)... 9, 2017  Demonstrating its commitment to representing ... for the Pharmaceutical Research and Manufacturers of America ... companies will now have to meet new research ... eligible to join PhRMA. "By putting ... sending a clear message that being a member ...
(Date:5/6/2017)... May 5, 2017   Provista , a proven leader ... 200,000 customers, today announced Jim Cunniff as the ... executive and business experience to Provista, including most recently serving ... California . He assumed his new role ... a great fit for Provista," says Jody Hatcher , ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... 2017 , ... In any business, follow up is critical to success. It ... at presenting treatment, there will always be some patients who can’t or won’t make ... best practices when it comes to presenting treatment. After the patient leaves, most ...
(Date:5/26/2017)... , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying for ... young scientists in the Parkinson’s field.     , The American Parkinson Disease Association (APDA) ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading ... sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a ... operations. With this platform, initializing devices and importing studies are just one-click operations. ...
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... 2017 , ... Rob Lowe acts as host and helps educate and inform ... hiking in American. Viewers can reconnect with America as it explores some of the ... consumers have looked for an inventive new place for a family vacation, and have ...
Breaking Medicine News(10 mins):